Proactive Investors - Run By Investors For Investors

Kazia Therapeutics substantial holder Willoughby Capital increases interest to 17.52%

Edison Investment Research has assigned an indicative valuation range of $84–135 million or $1.35–2.17 per share for Kazia.
Kazia Therapeutics substantial holder Willoughby Capital increases interest to 17.52%
Kazia shares held by Willoughby were previously held by Hishenk Pty Ltd

Kazia Therapeutics Ltd (ASX:KZA) substantial holder Hishenk Pty Ltd has increased its interest in the company from 17.4% to 17.52% after purchasing 55,000 shares on-market.

This comes after the holder reiterated its confidence in the biotechnology company’s oncology drug develoomet last week by increasing its share to 17.4% from 13.8%.

Due to a restructure, the Kazia shares are now held by Willoughby Capital Pty Ltd ATF Willoughby Capital Trust, an associated entity of Hishenk due to common directors and shareholders.

 

Kazia is developing GDC-0084 brain penetrant PI3K inhibitor GDC-0084 and a third generation benzopyran drug, Cantrixil.

Licensed from Genentech in October 2016, GDC-0084 is a novel targeted therapy that inhibits the PI3K pathway, important in many forms of cancer and activated in 85-90% of GBM cases.

Glioblastoma multiforme is the most common and aggressive form of primary brain cancer, with chemotherapy treatment temozolomide only effective in one-third of patients.

Furthermore, the median survival rate is 12-15 months from diagnosis, meaning there is demand in the market for superior treatments.

View full KZA profile View Profile

Kazia Therapeutics Ltd Timeline

Related Articles

doctor
June 11 2019
Oncimmune is a specialist in the field of immunodiagnostics
Surgery
February 21 2019
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier
Alliance
April 05 2019
Chief executive Peter Butterfield said the company has started 2019 well-positioned for growth after a strong performance in 2018.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use